S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:CDMO

Avid Bioservices (CDMO) Stock Price, News & Analysis

$6.98
+0.19 (+2.80%)
(As of 03/27/2024 ET)
Today's Range
$6.51
$7.00
50-Day Range
$6.09
$8.79
52-Week Range
$4.07
$21.05
Volume
712,315 shs
Average Volume
2.19 million shs
Market Capitalization
$441.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.25

Avid Bioservices MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
104.2% Upside
$14.25 Price Target
Short Interest
Bearish
17.14% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.96
Upright™ Environmental Score
News Sentiment
0.44mentions of Avid Bioservices in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$31,527 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.06) to $0.15 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.11 out of 5 stars

Medical Sector

193rd out of 939 stocks

Pharmaceutical Preparations Industry

79th out of 430 stocks

CDMO stock logo

About Avid Bioservices Stock (NASDAQ:CDMO)

Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services of biologics for the biotechnology and biopharmaceutical industries. The company offers various services, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.

CDMO Stock Price History

CDMO Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
CDMO Dec 2024 10.000 call
CDMO Apr 2024 15.000 call
CDMO Dec 2024 2.500 call
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Why Is Avid Bioservices (CDMO) Stock Down 30% Today?
CDMO Mar 2024 7.500 put
Avid Bioservices: Don't Miss The Bigger Picture
See More Headlines
Receive CDMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avid Bioservices and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
6/21/2023
Today
3/27/2024
Next Earnings (Estimated)
4/01/2024
Fiscal Year End
4/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CDMO
Employees
365
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.25
High Stock Price Target
$20.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+104.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$560,000.00
Pretax Margin
-8.22%

Debt

Sales & Book Value

Annual Sales
$149.27 million
Cash Flow
$0.16 per share
Book Value
$3.03 per share

Miscellaneous

Free Float
61,728,000
Market Cap
$441.42 million
Optionable
Optionable
Beta
1.65
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

CDMO Stock Analysis - Frequently Asked Questions

Should I buy or sell Avid Bioservices stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CDMO shares.
View CDMO analyst ratings
or view top-rated stocks.

What is Avid Bioservices' stock price target for 2024?

4 brokers have issued 1-year price targets for Avid Bioservices' stock. Their CDMO share price targets range from $7.00 to $20.00. On average, they expect the company's stock price to reach $14.25 in the next year. This suggests a possible upside of 104.2% from the stock's current price.
View analysts price targets for CDMO
or view top-rated stocks among Wall Street analysts.

How have CDMO shares performed in 2024?

Avid Bioservices' stock was trading at $6.50 at the start of the year. Since then, CDMO stock has increased by 7.4% and is now trading at $6.98.
View the best growth stocks for 2024 here
.

Are investors shorting Avid Bioservices?

Avid Bioservices saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 10,840,000 shares, an increase of 64.5% from the February 29th total of 6,590,000 shares. Based on an average daily volume of 1,360,000 shares, the days-to-cover ratio is presently 8.0 days.
View Avid Bioservices' Short Interest
.

When is Avid Bioservices' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024.
View our CDMO earnings forecast
.

How were Avid Bioservices' earnings last quarter?

Avid Bioservices, Inc. (NASDAQ:CDMO) announced its earnings results on Wednesday, June, 21st. The biopharmaceutical company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.07. The biopharmaceutical company had revenue of $39.80 million for the quarter, compared to analyst estimates of $39 million. Avid Bioservices had a negative net margin of 8.12% and a negative trailing twelve-month return on equity of 5.18%. During the same quarter in the previous year, the company posted $0.04 earnings per share.

What ETFs hold Avid Bioservices' stock?

ETFs with the largest weight of Avid Bioservices (NASDAQ:CDMO) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE) and Franklin Genomic Advancements ETF (HELX).Invesco S&P SmallCap Health Care ETF (PSCH).

When did Avid Bioservices' stock split?

Shares of Avid Bioservices reverse split before market open on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What guidance has Avid Bioservices issued on next quarter's earnings?

Avid Bioservices updated its third quarter 2024 earnings guidance on Wednesday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $33.8 million-$33.8 million, compared to the consensus revenue estimate of $34.2 million.

What is Roger Lias' approval rating as Avid Bioservices' CEO?

5 employees have rated Avid Bioservices Chief Executive Officer Roger Lias on Glassdoor.com. Roger Lias has an approval rating of 49% among the company's employees. This puts Roger Lias in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 63.0% of employees surveyed would recommend working at Avid Bioservices to a friend.

What other stocks do shareholders of Avid Bioservices own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avid Bioservices investors own include Array Technologies (ARRY), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Micron Technology (MU), QUALCOMM (QCOM), NVIDIA (NVDA), Novavax (NVAX) and Pfizer (PFE).

Who are Avid Bioservices' major shareholders?

Avid Bioservices' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.72%), Vanguard Group Inc. (5.72%), Royal Bank of Canada (3.92%), Palisade Capital Management LP (2.81%), Wellington Management Group LLP (2.34%) and New York State Common Retirement Fund (1.20%). Insiders that own company stock include Daniel R Hart, Gregory Sargen, Joseph Carleone, Mark R Ziebell, Matthew R Kwietniak, Nicholas Stewart Green, Richard A Richieri and Richard B Hancock.
View institutional ownership trends
.

How do I buy shares of Avid Bioservices?

Shares of CDMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CDMO) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners